You are here: Home: LCU 4 | 2006 : Vincent A Miller, MD: Select publications

SELECT PUBLICATIONS

Asahina H et al. A phase II study of gefitinib as a first-line therapy for advanced non-small cell lung cancers with epidermal growth factor receptor (EGFR) gene mutations. Proc ASCO 2006;Abstract 13014.

Fossella F et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21(16):3016-24. Abstract

Herbst RS et al; TRIBUTE Investigator Group. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23(25):5892-9. Abstract

Miller VA et al. EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. Presentation. Proc ASCO 2006;Abstract 7003.

Paz-Ares L et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Proc ASCO 2006;Abstract 7020.

Riely GJ et al. Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G (“acquired resistance”) followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001). Proc ASCO 2006;Abstract 7065.

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599. Proc ASCO 2005;Abstract 4.

Strauss GM et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Proc ASCO 2006;Abstract 7007.

Sunaga N et al. Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations. Proc ASCO 2006;Abstract 7183.

Sutani A et al. Phase II study of gefitinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LNA PCR clamp. Proc ASCO 2006;Abstract 7076.

Table of Contents

Top of Page